Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 18, 2020
- Accepted in final form February 22, 2021
- First Published May 18, 2021.
Author Disclosures
- Francesc Graus, MD, PhD* (francesc.graus{at}idibaps.org),
- Alberto Vogrig, MD* (alberto.vogrig{at}gmail.com),
- Sergio Muñiz-Castrillo, MD* (ext-sergio.muniz{at}chu-lyon.fr),
- Jean-Christophe G. Antoine, MD, PhD (j.christophe.antoine{at}chu-st-etienne.fr),
- Virginie Desestret, MD, PhD (virginie.desestret{at}chu-lyon.fr),
- Divyanshu Dubey, MD (dubey.divyanshu{at}mayo.edu),
- Bruno Giometto, MD (bruno.giometto{at}apss.tn.it),
- Sarosh R. Irani, MD, PhD (sarosh.irani{at}ndcn.ox.ac.uk),
- Bastien Joubert, MD, PhD (bastien.joubert{at}chu-lyon.fr),
- Frank Leypoldt, MD, PhD (frank.leypoldt{at}uksh.de),
- Andrew McKeon, MD (mckeon.andrew{at}mayo.edu),
- Harald Prüss, MD (harald.pruess{at}charite.de),
- Dimitri Psimaras, MD (dimitri.psimaras{at}aphp.fr),
- Laure Thomas, MD (laure.thomas{at}chu-lyon.fr),
- Maarten J. Titulaer, MD, PhD (m.titulaer{at}erasmusmc.nl),
- Christian A. Vedeler, MD, PhD (christian.alexander.vedeler{at}helse-bergen.no),
- Jan J. Verschuuren, MD, PhD (j.j.g.m.verschuuren{at}lumc.nl),
- Josep Dalmau, MD, PhD (josep.dalmau{at}uphs.upenn.edu) and
- Jerome Honnorat, MD, PhD
- Francesc Graus, MD, PhD* (francesc.graus{at}idibaps.org),
NONE
NONE
NONE
Associated Editor for MedLink Neurology
I hold a patent for the use of IgLON5 antibodies as diagnostic test
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I receive royalties from Euroimmun for the use of IgLON5 as an autoantibody test
NONE
NONE
NONE
- Alberto Vogrig, MD* (alberto.vogrig{at}gmail.com),
NONE
NONE
NONE
BMC Neurology, Editorial Board Member, 2020-2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
European Academy of Neurology (EAN)
NONE
NONE
NONE
NONE
NONE
NONE
- Sergio Muñiz-Castrillo, MD* (ext-sergio.muniz{at}chu-lyon.fr),
- Jean-Christophe G. Antoine, MD, PhD (j.christophe.antoine{at}chu-st-etienne.fr),
Association Française contre les Myopathies
NONE
Pfizer-Travel
NONE
Patents on the use of anti-CRMP5 and anti-FGFR3 antibodies for diagnostic purpose
NONE
NONE
Pfizer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Virginie Desestret, MD, PhD (virginie.desestret{at}chu-lyon.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Divyanshu Dubey, MD (dubey.divyanshu{at}mayo.edu),
- Bruno Giometto, MD (bruno.giometto{at}apss.tn.it),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sarosh R. Irani, MD, PhD (sarosh.irani{at}ndcn.ox.ac.uk),
Encephalitis Society and Autoimmune Encephalitis Alliance (non-profit, charity). ADC therapeutics, Immunovant and UCB (commercial)
NONE
SRI has received honoraria for speaking at scientific conferences, including the Movement Disorder Society, Dublin Neuroimunology Symposium, Korean Encephalitis meeting and Bethel Epilepsy Symposium.
NONE
SRI receives royalties on patent application WO/2010/046716 entitled 'Neurological Autoimmune Disorders'. The patent has been licensed for the development of assays for LGI1 and other VGKC-complex antibodies.
NONE
NONE
1. Commercial. MedImmune Ltd. 2. ADCT 3. Minnetronix Neuro Inc 4. UCB Pharma 5. Medicolegal projects (various)
NONE
NONE
NONE
Commercial: SRI has received research funding from UCB, CSL Behring and ONO pharmaceuticals
S.R.I has received a NIHR fellowship, Department of Health, UK to fund his DPhil/PhD
SRI received funding support from a Wellcome Intermediate Clinical Fellowship, BMA Research Grants - Vera Down grant, the Fulbright UK- US commission and the MS society (2012-2013).
NONE
NONE
NONE
For VGKC-complex antibody patent, as described above. Royalties paid by OUI.
NONE
NONE
NONE
- Bastien Joubert, MD, PhD (bastien.joubert{at}chu-lyon.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
European Academy of Neurology awarded the following grant: EAN Research Training Fellowship 2019 Institut Servier Research Grant 2020
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Leypoldt, MD, PhD (frank.leypoldt{at}uksh.de),
(1) Roche (2) Biogen (3) Alexion (4) Novartis
NONE
(1) Grifols (2) Teva (3) Biogen (4) Fresenius (5) Bayer (6) Novartis (6) Roche (6) Novartis (7) Merck (8) Roche (9) Alexion
Neurology: Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
NONE
NONE
NONE
Institute of Laboratory Medicine, University Hospital Schleswig- Holstein Campus Kiel, Germany, commercial antibody testing service, 20%
NONE
(1) German Ministry of Education and Research (BMBF) Speaker, PI 2019 01GM1908A (2) German Research Council (GRC, DFG), PI, 2019 LE 3064/2-1
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew McKeon, MD (mckeon.andrew{at}mayo.edu),
NONE
NONE
NONE
I am a member of the editorial board of Neurology: Neuroimmunology and Neuroinflammation
Patent applications pending: Septin 5, Septin 7, GFAP, PDE10A, Kelch-11 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders
NONE
NONE
NONE
NONE
NONE
NONE
Euroimmun Alexion
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Harald Prüss, MD (harald.pruess{at}charite.de),
- Dimitri Psimaras, MD (dimitri.psimaras{at}aphp.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Laure Thomas, MD (laure.thomas{at}chu-lyon.fr),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Maarten J. Titulaer, MD, PhD (m.titulaer{at}erasmusmc.nl),
NONE
NONE
NONE
(1) Neurology: Neuroimmunology & Neuroinflammation, since June 2014
(1) filed a patent for "methods for typing neurological disorders and cancer, and devices for use therein" specifically about diagnostics for anti-GABAB receptor antibodies and KCTD antibodies.
NONE
NONE
NONE
NONE
NONE
NONE
(1) Guidepoint Global LLC, research funds for consultancy; (2) Novartis, research funds for teaching; (3) unrestricted research grant from Euroimmun AG.
(1) supported by the Netherlands Organisation for Scientific Research (NWO, Veni incentive and Memorabel initiative)
(1) Previously supported by an ErasmusMC fellowship
(1) supported by the Dutch Epilepsy Foundations, projectnumbers 14-19 and 19-08.
NONE
NONE
NONE
NONE
NONE
NONE
- Christian A. Vedeler, MD, PhD (christian.alexander.vedeler{at}helse-bergen.no),
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jan J. Verschuuren, MD, PhD (j.j.g.m.verschuuren{at}lumc.nl),
Myasthenia Foundation of America (MGFA) medical/scientific advisory board. Study Steering Committee of Argenx. Advisory meeting for Rapharma.
NONE
World Muscle Society, travel grant for keynote speaker lecture
Journal of Neuromuscular Diseases, member editorial board, 2014-now
Patents on MuSK myasthenia gravis
NONE
NONE
The Neurology department of the LUMC has received fees from Argen-X, and NMDPharma because of consultancies
NONE
NONE
NONE
Argenx and NMDPharma research agreement
NONE
NONE
Princes Beatrix Spierfonds, grant for MG research, Prinicpal investigator.
NONE
NONE
The LUMC received royalties for a diagnostic antibody test from TECAN/IBL.
NONE
NONE
NONE
- Josep Dalmau, MD, PhD (josep.dalmau{at}uphs.upenn.edu) and
SAGE therapeutics
NONE
NONE
Neurology, Neuroimmunology and Neuroinflammation Neurology Annals Neurology
Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.
Neurology- UpToDate, Wolters Kluwer contributing author, receive royalties Medlink Neurology contributing author, receive royalties
NONE
Advance Medical
NONE
NONE
NONE
Research support (allosteric modulation of NMDAR) from SAGE Therapeutics
-Instituto Carlos III/FEDER (FIS, 17/00234, CIBERER CB15/00010, Proyectos Integrados de Excelencia, PIE 16/00014 and AC18/00009). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya
NONE
Safra Foundation Sage therapeutics Cellex Foundation La Caixa Health Foundation
NONE
NONE
Ma2 autoantibody test (tech/invention), Athena Diagostics via Memoral Sloan Kettering, current NMDA receptor, GABA(B) receptor autoantibody tests (tech/invention), Euroimmun, Inc via University of Pennsylvania, current GABA(A) receptor, DPPX and IgLON5 autoantibody tests (tech/invention), Euroimmun, Inc via Institucio Catalana de Recerca i Estudis Avancats (ICREA); Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), current
NONE
NONE
NONE
- Jerome Honnorat, MD, PhD
Scientific advisory board for Bristol Meyers Squibb
NONE
NONE
NONE
receives royalties from licensing fees to Athena Diagnostics, Euroimmun, and ravo Diagnostika for a patent for the use of CV2/CRMP5 as diagnostic tests.
NONE
NONE
NONE
NONE
NONE
NONE
Research support from CSL Behring France
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centre de Référence National pour les Syndromes Neurologiques Paranéoplasique (A.V., S.M.-C., J.-C.G.A., V.D., B.J., L.T., J.H.), Hôpital Neurologique, Hospices Civils de Lyon; SynatAc Team (A.V., S.M.-C., V.D., B.J., L.T., J.H.), NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310, Lyon; Université Claude Bernard Lyon 1 (A.V., S.M.-C., V.D., B.J., L.T., J.H.), Université de Lyon; Service de Neurologie (J.-C.G.A.), CHU de Saint-Etienne, France; Department of Neurology (D.D., A.M.), Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Neurology Unit (B.G.), Trento Hospital, Azienda Provinciale per I Servizi Sanitari (APSS) di Trento, Italy; Oxford Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, United Kingdom; Neuroimmunology Section (F.L.), Institute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel/Lübeck; German Center for Neurodegenerative Diseases (DZNE) Berlin (H.P.), and Department of Neurology and Experimental Neurology (H.P.), Charité–Universitätsmedizin Berlin, Germany; Centre de Compétence des Syndromes Neurologiques Paranéoplasiques et Encéphalites Autoimmunes (D.P.), Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Department of Neurology 2 Mazarin (D.P.), and INSERM U 1127 (D.P.), CNRS UMR 7225, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière Groupe, Hospitalier Pitié-Salpêtriêre et Université Pierre et Marie Curie-Paris 6, AP-HP, France; Department of Neurology (M.J.T.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Clinical Medicine (C.A.V.), University of Bergen; Department of Neurology (C.A.V.), Haukeland University Hospital; Neuro-SysMed–Centre of Excellence for Experimental Therapy in Neurology (C.A.V.), Departments of Neurology and Clinical Medicine, Bergen, Norway; and Neurology Department (J.J.V.), Leiden University Medical Center, the Netherlands.
- Correspondence
Dr. Honnorat jerome.honnorat{at}chu-lyon.fr
Article usage
Cited By...
Letters: Rapid online correspondence
- Author Response: Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
- Francesc Graus, Emeritus investigator, Institut d'Investigacions Biomèdiques August Pi i Sunyer. Barcelona, Spain
Submitted November 14, 2021 - Reader Response: Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes
- Yin-Xi Zhang, Neurologist, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University
- Meng-Ting Cai, Neurologist, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University
- Yang Zheng, Neurologist, Department of Neurology, Second Affiliated Hospital, School of Medicine, Zhejiang University
Submitted June 22, 2021
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease
Dr. Rizwan S. Akhtar and Dr. Sarah Brooker
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Neurologic autoimmunity and immune checkpoint inhibitorsAutoantibody profiles and outcomesElia Sechi, Svetomir N. Markovic, Andrew McKeon et al.Neurology, August 13, 2020 -
Article
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitorsAlberto Vogrig, Marine Fouret, Bastien Joubert et al.Neurology: Neuroimmunology & Neuroinflammation, August 07, 2019 -
Article
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in FranceJulien Hébert, Benjamin Riche, Alberto Vogrig et al.Neurology: Neuroimmunology & Neuroinflammation, August 26, 2020 -
Articles
GABAB receptor antibodies in limbic encephalitis and anti-GAD–associated neurologic disordersA. Boronat, L. Sabater, A. Saiz et al.Neurology, February 28, 2011